Taysha Gene Therapies (TSHA) Equity Average (2020 - 2026)

Taysha Gene Therapies has disclosed Equity Average across 7 years of filings, most recently posting $229.4 million for Q1 2026.

• Equity Average for Q1 2026 came in at $229.4 million, up 262.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $229.4 million (up 262.51% YoY), and the FY2025 annual result was $159.2 million, up 117.44% from the prior year.
• Equity Average came in at $229.4 million for Q1 2026 at Taysha Gene Therapies, down from $233.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $233.9 million in Q3 2025 to a low of -$43.1 million in Q3 2023.
• The 5-year median for Equity Average is $64.4 million (2024), against an average of $77.4 million.
• Across the five-year window, Equity Average tumbled 299.56% in 2023 and soared 1019.97% in 2024, its largest moves.
• Taysha Gene Therapies' Equity Average stood at $5.8 million in 2022, then soared by 121.62% to $12.9 million in 2023, then jumped by 520.85% to $80.2 million in 2024, then jumped by 190.62% to $233.0 million in 2025, then decreased by 1.51% to $229.4 million in 2026.
• The last three Equity Average figures came in at $229.4 million (Q1 2026), $233.0 million (Q4 2025), and $233.9 million (Q3 2025), per Business Quant data.